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Abstract
The mechanism by which HIV and HCV cooperatively accelerate hepatocyte damage is not clearly understood; however,
each virus affects the TRAIL: TRAIL- receptor system. We, therefore, questioned whether the independent effects of HCV and
HIV combine to synergistically result in TRAIL dependent hepatocyte killing. We describe that Huh7 hepatocytes treated
with HIV gp120 results in both increase TRAIL-R2 expression and an acquired sensitivity to TRAIL mediated killing. Moreover
HCV infection and HCV core expression alone in Huh7 cells upregulates TRAIL. Co-incubation of HIV gp120 primed
hepatocytes with HCV core expressing hepatocytes results in the selective death of the HIV gp120 primed hepatocytes that
is selectively blocked by TRAIL–R2-Fc fusion protein. Liver biopsies from HIV mono-infected patients have increased TRAIL-
R2; biopsies from HCV infected patients have increased TRAIL, while co-infected liver biopsies have increased PARP cleavage
within hepatocytes indicating enhanced apoptosis. These findings suggest a pathogenic model to understand why HIV/HCV
co-infection accelerates liver injury.
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Introduction
HCV and HIV infections are frequent worldwide; in the USA
more than four million people are infected with HCV, which can
cause liver fibrosis, cirrhosis, end-stage liver disease, and
hepatocellular carcinoma. Approximately 30% of HIV- infected
individuals are co-infected with Hepatitis C Virus (HCV) due to
their similar modes of transmission [1], as evidenced by the fact
that 80% of intravenous drug users (IVDU) infected with HIV are
co-infected with HCV. HIV/HCV co-infection results in an
increase in morbidity and mortality than occurs with either HIV
or HCV mono-infection [2,3].
The pathologic mechanism(s) underlying the accelerated liver
disease associated withHCV during HIV co-infection are not clearly
understood, but have been proposed to be due to a loss of HCV-
specific CD4+ T cells[4]. Such a model accounts for improvements
in liver disease which occurs after highly active antiretroviral therapy
(HAART)-induced immune reconstitution [5], and lower CD4+ T
cell counts being associated with worsened liver function [6].
Alternative models include HIV infection altering the host cytokine
response to HCV [7], enhancing the ability of HCV to infect target
cells [8], or HIV exacerbating the cytotoxicity of HCV [9]. It also
has been suggested that HIV and HCV may cooperatively induce
hepatocyte injury through apoptosis [10]. Hepatocyte apoptosis in
turn leads to liver fibrogenesis and ultimately cirrhosis [11].
Apoptosis contributes to many liver diseases, including viral
hepatitis. Activation of the TNF super-family of death inducing
receptors results in hepatocyte apoptosis in several models of liver
disease [12]. Hepatocytes express Fas (CD95), TRAIL-R1 and –
R2 (TNF-related apoptosis-inducing ligand receptor -1 and -2)
(DR5/CD262) and TNF-R1 (TNF receptor type 1) on the cell
surface [13,14,15]. After ligation by their respective ligands, these
death receptors aggregate and form the death inducing signaling
complex (DISC) which causes caspase 8 activation that ultimately
results in mitochondrial membrane permeabilization, formation of
the apoptosome, which in turn activates effector proteases and
nucleases, resulting in the phenotypic changes of apoptosis [16].
There is increasing evidence that liver damage caused by HCV
is due to hepatocyte apoptosis, with more hepatocyte apoptosis
being present in livers from HCV-infected compared to non-
infected individuals [17,18]. Using antibodies specific for active
caspase-3 and -7, as well as the cleaved form of PARP, caspase
activation and PARP cleavage is increased in livers infected with
HCV compared to non-infected livers and caspase activation, as
well as hepatocyte apoptosis are directly correlated with the grade
of necro-inflammatory injury (reviewed in [18,19]). Hepatocyte
apoptosis may be caused by both immune mechanisms and direct
cytopathic effects of HCV [20]. Fas (CD95) has been the most
thoroughly investigated death inducing ligand during HCV
infection. Fas is expressed on hepatocytes during HCV infection
and levels correlate with the severity of liver inflammation. Cell
surface associated Fas and FasL levels are also associated with
increased hepatocyte apoptosis during HIV/HCV infection
[15,17]. Of note, several recent reports indicate that hepatocytes
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obtained from patients with HCV also have greater TRAIL
expression than hepatocytes from uninfected controls [21,22].
We have reported that X4 HIV gp120 envelope protein binding
to CXCR4 on the surface of human hepatocytes activates JNK II,
causing a transcriptional up regulation of the TRAIL receptor,
TRAIL-R2 (DR5/CD262), which also is associated with an
acquired state of TRAIL sensitivity [14]. More recently this
observation has been extended to JFH1 HCV infected Huh 7.5.1
cells, where inactivated HIV causes upregulation of TRAIL-R2,
and initiates a TRAIL dependent apoptosis [23] Altogether, such
data support a model wherein HIV enhances TRAIL-R2
expression and TRAIL sensitivity, while an unknown factor
associated with HCV infection promotes TRAIL expression and
function. The purpose of the current report is to discover which
factor associated with HCV causes hepatocyte expression of
TRAIL, and to determine whether these changes result in the
autocrine or paracrine death of HCV expressing, or HIV treated
cells, and to determine whether the changes which are occur in
vitro are also seen in vivo.
Results
X4 HIV Gp120 Increases TRAIL-R2 but not TRAIL on Huh7
cells
It is established that HIV increases TRAIL-R2 expression on
hepatocytes, renders the cell sensitive to TRAIL, and indepen-
dently induces a low degree of hepatocyte apoptosis [14,24].
Therefore, we questioned whether HIV gp120 also increases
TRAIL expression, which then might cause the observed
hepatocyte apoptosis. As we have previously demonstrated, there
was greater TRAIL-R2 expression, but not TRAIL-R1, -R3 nor –
R4 when Huh7 cells were incubated with increasing concentra-
tions of HIV gp120 (Fig. 1A and B)[14]. This is confirmed by real
time PCR (Fig. 1C and D). However, increasing concentrations of
HIV gp120 did not alter TRAIL expression on Huh7 cells by flow
cytometry (Fig. 2A) or Western blot (Fig. 2C). Therefore, HIV
gp120 increases TRAIL-R2 expression on Huh7 cells, but does
not alter TRAIL expression. Although the Huh7 cell is TRAIL
sensitive after HIV gp120 treatment, there is little spontaneous
death of the hepatocyte without the addition of exogenous TRAIL
[14].
HCV Core Protein Increases TRAIL but not TRAIL-R2 on
Huh7 cells
It has been previously observed that HCV infection in the JFH1
HCV model using Huh7.5.1 cells results in enhanced TRAIL
expression [23], and a similar effect has been reported to occur
after HCV infection of livers in vivo [21,22,25]. Since it remains
unknown what factor (s) associated with HCV are necessary or
sufficient for this effect, we questioned whether individual HCV
protein(s) could induce TRAIL expression in hepatocytes.
Ultimately we focused on the HCV core protein since it is highly
conserved and has been associated with several immunomodula-
tory functions [26,27], including modulation of apoptosis signaling
[28,29]. Huh7 cells were transfected with HCV genotype 1b core
protein, as this represents the most common HCV genotype in
North America and Western Europe, and patients with this virus
have accelerated liver disease [30]. Cells expressing HCV core had
increased TRAIL surface expression compared to control, as
determined by flow cytometry (Fig. 3A and B) and western blot
(Fig. 3D and E). A similar increase in TRAIL was seen following
HIV infection using JFH1 HCV in Huh7.5.1 cells (Fig. 3C). The
HCV core protein expression system is doxycycline responsive,
however, doxycycline alone did not change TRAIL levels (Fig. 3F).
The increase in TRAIL only occurred when HCV core protein
was intracellularly expressed and not by extracellular soluble HCV
core protein (Fig. 3G). Conversely, HCV core expression in Huh7
cells did not increase TRAIL-R2 expression (Fig. 3H), demon-
strating that HIV and HCV exert complementary effects on the
hepatocyte; HCV core protein increases TRAIL, but not TRAIL-
Figure 1. HIV gp120 Increases TRAIL-R2. (A) Huh7 cells were incubated with increasing concentrations of HIV gp120 and analyzed for TRAIL-
Receptor expression by Flow cytometry for TRAIL-R1, -R2, -R3, -R4 (BSA = black, HIV gp120= Grey), (B and D) Western blot (C) or real time PCR.
doi:10.1371/journal.pone.0027171.g001
HCV Hepatocytes Kill HIV Hepatocytes through TRAIL
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R2 while HIVgp120 increases TRAIL-R2 and confers an acquired
state of TRAIL sensitivity, while not impacting TRAIL levels.
HIV increases TRAIL-R2 and HCV Increases TRAIL in vivo
In our model, HIV gp120 treatment increases TRAIL-R2
expression on Huh7 cells, and HCV core protein increases TRAIL
expression. In order to confirm that these changes also occur in
vivo, liver samples from 10 uninfected individuals, 10 HIV infected,
10 HCV infected and 10 HIV/HCV co-infected individuals were
stained by immunohistochemistry for TRAIL-R2, TRAIL and
cleaved PARP as a measure of apoptosis (Fig. 4). Normal liver
samples taken from individuals not infected with HIV or HCV
have minimal TRAIL-R2, and minimal TRAIL expression.
TRAIL-R2 levels are increased in liver samples from HIV-
infected individuals and TRAIL staining is increased in HCV
infected livers. Liver samples from HIV/HCV co-infected
individuals have increased TRAIL and TRAIL-R2 staining
(Fig. 4). Furthermore, HIV/HCV co-infected livers have greater
hepatocyte apoptosis, as determined by staining of cleaved PARP,
than HIV mono-infected, HCV mono-infected or uninfected
livers, consistent with previous reports[17,31].
Co-incubation of HIV and HCV Treated Huh7 cells Results
in a TRAIL Mediated Apoptosis
Our observation of increased TRAIL-R2 expression and
enhanced TRAIL sensitivity induced by HIV and increased
TRAIL expression induced by HCV core, predicts that the
presence of both viruses should result in augmented hepatocyte
death. To test this hypothesis, Huh7 cells were stained with the
lipophilic dye Dio, treated with HIV gp120 and then co-incubated
at increasing effector-to-target ratios with HCV core protein
transfected Huh7 cells. Following an overnight incubation, cells
were analyzed by flow cytometry for active-caspase-3 expression to
determine the levels of apoptosis in the Dio positive (HIV gp120
treated) and Dio negative (HCV core expressing) cells. There was
no Dio leak between hepatocytes (data not shown). HIV core
expressing (Dio positive) target cells had greater apoptosis than
HCV treated hepatocytes and this effect increased with increasing
E:T ratios (Fig. 5A). The effect was not present when target cells
were treated with control protein rather than HIV gp120 (Fig. 5B).
The HCV core expressing (Dio negative) effector cells had no
greater apoptosis than untreated cells (data not shown). Pre-
incubating the Huh7 cells with the TRAIL-R2-Fc fusion protein,
blocked the increased apoptosis that resulted from co-incubating
HIV and HCV treated hepatocytes (Fig. 5C and 5D). These data
demonstrate that HIV gp120 increases TRAIL-R2 expression and
TRAIL confers sensitivity in treated hepatocytes; HCV core
protein increases TRAIL expression in hepatocytes and co-
incubating the HIV gp120 and HCV core expressing liver cells
results in an accelerated TRAIL mediated apoptosis, selectively in
the HIV treated cells. The relevance of this in vivo is suggested by
similar changes being observed in liver biopsies from patients with
HIV infection, HCV infection or both.
Discussion
It is clear that HIV worsens the course of HCV infection by
increasing hepatocyte apoptosis, liver fibrosis and inflammation
and quickening the progression to end stage liver disease [6]. It
remains unclear how HIV propagates HCV liver disease, but
clinical evidence demonstrates that decreasing HIV viral replica-
tion and improving CD4+ T cell counts, improves markers of liver
disease [5,6].
Figure 2. HIV gp120 Does not Increase TRAIL. (A and B) Huh7 cells were incubated with increasing concentrations of HIV gp120 and analyzed
for TRAIL expression by Flow cytometry (C and D) and Western blot.
doi:10.1371/journal.pone.0027171.g002
HCV Hepatocytes Kill HIV Hepatocytes through TRAIL
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HIV RNA and p24 antigen have been isolated from liver
samples, presumably from HIV infected immune cells, indicating
that HIV proteins are in close proximity to hepatocytes during
HIV infection [32,33]. These proteins also contribute to the
depletion of CD4+ T cells through multiple mechanisms,
including HIV gp120 mediated bystander killing of uninfected
Figure 4. In vivo analysis of TRAIL, TRAIL-R2 and Apoptosis in Human Livers. Liver samples from 10 HIV infected, 10 HCV infected, 10 HIV/
HCV infected or 10 uninfected individuals were stained by Immunohistochemistry for TRAIL, TRAIL-R2 or cleaved PARP. The images were taken with
an Olympus Microscope with the 20x objective (TRAIL, TRAIL-R2), and 40x objective (PARP). Representative samples are shown.
doi:10.1371/journal.pone.0027171.g004
Figure 3. HCV core protein Increases TRAIL but not TRAIL-R2. (A and B) Huh7 cells were transfected with HCV core protein for increasing
amounts of time and then analyzed for TRAIL expression by Flow cytometry or (D and E) Western blot. (C) Huh7.5 cells were infected with the JFH1
HCV genotype 2a and analyzed for TRAIL by Western blot. (F) Huh7 cells were treated with doxycycline for increasing amounts of time and analyzed
for TRAIL by Western blot (G) Huh7 cells were treated with increasing concentrations of soluble HCV core protein or control and analyzed for TRAIL by
Western blot (H) In parallel HCV core transfected Huh7 cells were analyzed for TRAIL-R2 expression by Western blot.
doi:10.1371/journal.pone.0027171.g003
HCV Hepatocytes Kill HIV Hepatocytes through TRAIL
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cells [34]. HIV gp120 also induces death of non-immune cells,
including neurons and hepatocytes [10,24,35,36]. Therefore, HIV
gp120 causes at least two distinct effects upon the liver: 1) low level
of background death [24] which may account for the increased
liver disease in HIV mono-infected patients compared to
uninfected patients, and 2) increasing TRAIL-R2 expression,
and co-incident acquired sensitivity to TRAIL mediated apoptosis
[14], which likely contributes to the accelerated course of co-
morbid liver disease during HCV co-infection.
Within our proposed model, one would expect increased
hepatocyte apoptosis during any disease states in which TRAIL
and TRAIL-R2 are increased. In addition to HIV gp120, a
number of other stimuli can increase TRAIL-R2 expression or
TRAIL sensitivity in hepatocytes. The Hepatitis B virus protein
MHBs(t) sensitizes human hepatocytes to TRAIL [37] and is
mediated via Bax signaling [38]. Free fatty acid induced steatosis
causes TRAIL sensitivity in human hepatocytes [39] which is
exacerbated by treatment with alcohol [22]. In addition, bile acids
increase TRAIL-R2 and induce TRAIL sensitivity in human
hepatocytes. This process is mediated via a c-Jun N-terminal
kinase-dependent pathway involving Sp1 [12]. Medications can
also sensitize cells to TRAIL mediated apoptosis and are being
investigated as a means to treat otherwise TRAIL resistant
cancers. Doxorubicin treatment, for instance, sensitizes glioblas-
toma cells [40] and liver cancer cells to TRAIL via the BH3-only
proteins Bim and Bid [41]. At supra-therapeutic levels, even HIV
protease inhibitors, such as Nelfinavir, can sensitize cells to TRAIL
[42]. This may in part explain why there is worse liver disease
during Hepatitis C Virus infection and any of these co-existing
conditions.
Several reports indicate that hepatocytes obtained from patients
with HCV have increased TRAIL expression compared to
hepatocytes from uninfected controls [21,22]. Our data expands
upon these observations with the novel findings that this effect
localizes to the HCV core protein. Moreover, we now report that
increased apoptosis occurs in hepatocytes when HCV core
expressing hepatocytes produce TRAIL which induces fratricidal
killing of HIV gp120 primed hepatocytes that manifest both
increased TRAIL-R2 as well as enhanced TRAIL sensitivity. This
model is further supported by immunohistochemistry in tissues
from HIV or HCV mono-infection, or HIV/HCV co-infection
where similar changes occur in vivo as what we observed in vitro.
While we demonstrate that HCV core protein alone is sufficient
to increase TRAIL expression, it is possible that other HCV
structural or non-structural proteins may also alter TRAIL
expression. Furthermore, our model does not exclude the
possibility that HCV infection triggers an indirect effect that in
turn regulates TRAIL expression. HCV infection results in a
number of alterations in the immune system most notably, HCV
causes a Type 1 interferon response. Type 1 interferon induces
TRAIL expression on NK cells which is associated with control of
HCV infection in patients [43]. Furthermore, in a cell culture
model, the HCV isolate JFH-1 resulted in an interferon response
which caused apoptosis of infected cells [44]. Interestingly, amino
Figure 5. Co-incubation of HIV/HCV treated hepatocytes kills HIV treated hepatocytes via TRAIL. (A) Huh7 cells expressing HCV core
were co-incubated with HIV gp120 treated hepatocytes at increasing effector-to-target ratios, and cell death of HIV treated (Dio positive) hepatocytes
were determined by flow cytometry for active caspase 3 expression. (B) HIV gp120 or BSA control treated cells were incubated with HCV core or mock
transfected cells and death analyzed in the gp120 or BSA treated cells. (C and D) HIV gp120 or BSA treated cells were incubated with HCV core or
mock transfected cells, in the presence or absence of a TRAIL-R2-Fc fusion protein, or control-Fc fusion protein, and cell death analyzed in the gp120
or BSA treated cells.
doi:10.1371/journal.pone.0027171.g005
HCV Hepatocytes Kill HIV Hepatocytes through TRAIL
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acid substitutions in the HCV core protein during clinical HCV
infections, alters the response to interferon based HCV therapy
[45], suggesting that HCV core plays a role in interferon mediated
effects and possibly TRAIL mediated apoptosis.
We propose a model of HIV/HCV mediate liver disease
whereby co-incubation of HIV gp120 treated and HCV core
expressing hepatocytes results in accelerated hepatocyte death
which is TRAIL mediated. Therefore, untreated HIV infection
would create a TRAIL sensitive hepatocyte with increased
TRAIL-R2 expression. When a second insult is introduced into
the liver, such as HCV infection, TRAIL production increases and
there is TRAIL mediated hepatocyte death; importantly TRAIL
antagonists reverse this process, suggesting a novel treatment
strategy for liver disease associated with HIV/HCV co-infection.
Methods
Chemicals and Reagents
The following chemicals and reagents were used for experi-
ments in the manuscript: Dulbecco’s modification of Eagle’s
medium (DMEM) (Mediatech Inc., Manassas, VA), Fetal bovine
serum (FBS) (Atlanta Biologicals Inc., Lawrenceville, GA),
Recombinant superkiller TRAIL (skTRAIL) (Alexis Biochemicals,
San Diego, CA), Recombinant HIV-1 IIIB envelope glycoprotein
120 (gp120) and recombinant human T- cell receptor sCD4
(Immuno Diagnostics Inc., Woburn, MA), Bovine serum albumin
(BSA) (Sigma Chemical Co, St. Louis, MO), anti-actin and anti-
tubulin antibodies (Molecular Probes, Carlsbad, CA), Antibodies
to TRAIL-R1, -R2, -R3, -R4 and isotype control, for flow
cytometry (BD Bioscience, San Diego, CA) and TRAIL-R2 for
Western blot (Capralogics Inc., Hardwick, MA), active caspase-3
(BD Biosciences), TRAIL-R2-Fc chimera (R & D system,
Minneapolis, MN), His tagged soluble HCV core protein
(PROSPEC, Ness Ziona, Israel).
Cell Viability
The human hepatocyte cell line Huh7 (ATCC) was cultured in
DMEM with 10% FBS and 100 units/mL of penicillin, 100 mg/
mL streptomycin, and 200 mM glutamine. The Huh7 cells were
plated at a density of 36105 cells/well in a 6 well plate. 5 mg/mL
HIV glycoprotein 120 IIIB [46] was used to prime Huh7 cells for
six hours, and then cells were incubated with 100 ng/mL of
skTRAIL or with HCV core transfected Huh7 cells for thirty six
hours. In some experiments, Huh7 cells were pre-incubated for
1 hour at 37 C with rhTRAIL-R2/Fc chimera (0.5 mg/ml) or
control before co-incubation. Apoptosis was determined by
staining for Active Caspase 3 and analyzing by flow cytometry,
as described below.
HCV Core Transfection
Huh7 cells were co-transfected with a mixture of supercoiled
pTet-on, pTts (Clontech) and pTRE2-191 and lipofectamine 2000
reagent (Invitrogen, CA). Transfected cells were grown in
complete culture medium for 24 h. To induce the conditional
expression of HCV-core protein, transfected cells were treated
with Doxycycline 1 mg/mL for the indicated period and the
expression of core was confirmed by western blot analysis.
Western Blots
Huh7 cells were treated with 5 mg HIV gp120 for 24 hours and
lysed in lysis buffer (20 mM Tris, pH 7.5, 150 mM NaCl, 2 mM
EDTA, 0.1% Triton-X100, 2 mg/ml aprotinin, 5 mg/ml leupep-
tin, 1 mM PMSF and 1 mM Saponin) on ice. Jurkat cells and
PHA and IL2 stimulated PBMCs were used for positive controls.
30 mg of protein was resolved on a 15% sodium dodecyl sulfate
polyacrylamide (SDS-PAGE) gel and electrotransferred to poly-
vinylidene fluoride (PVDF) membranes (Millipore Corporation,
Bedford, MA). Membranes were blocked with 5% nonfat milk in
TBST [Tris base (10 mM), NaCl (150 mM), Tween (0.1%),
pH 7.5] for two hours at room temperature and probed with anti-
TRAIL-R2 (1:1000) antibodies overnight at 4 C. Actin (Sigma, St.
Louis, MO) was used as a loading control and intensity was
measured using EL Logic 2200 imaging software system.
Real Time Quantitative PCR
Total RNA was isolated from control or GP120 (1 mg/ml)
treated Huh7 cells for 48 h, using Qiagen RNeasy mini kit
(Qiagen, Valencia, CA) and reverse transcribed using the ABI
High Capacity cDNA Reverse Transcription Kit (Applied
Biosystems) with 2.5 mM random oligos, and 1 mg of RNA. The
cDNA was amplified in 25 ml of PCR buffer with Platinum SYBR
Green qPCR SuperMix-UDG with ROX kit (Invitrogen, CA) in
the presence of TRAIL-R2 or actin specific primers (sense primer
for TRAIL-R2 59-AAGACCCTTGTGCTCGTTGT - 39, anti-
sense primer 59-AGGTGGACACAATCCCTCTG - 39, actin
sense primer 59 -GAAACTACCTTCAACTCCATC - 39) and
antisense primer 59 –CGAGGCCAGGATGGAGCCGCC -39.
The PCR conditionsincluded a hot-start by 95uC for 2 min
followed by 40 cycles of 95uC for 15 s, 60uC for 1 min. Samples
were run in triplicates on the ABI PRISM 7700HT sequences
detection system (Applied Biosystems) to determine the threshold
cycle (CT). To determine the variation on mRNA expression, we
analysis according to the Delta-Delta threshold (Ct) method, each
Ct value was first normalized to the respective beta-actin Ct value.
Flow Cytometry
Huh7 cells were harvested, washed in cold PBS, and fixed in 2%
paraformaldehyde overnight at 4 C. Cells were blocked with 2%
BSA/PBS and stained with phycoerythrin (PE) conjugated anti-
human anti-TRAIL-R1,-R2, -R3, -R4 or isotype control mAb
(1:40) or rabbit polyclonal anti-active caspase-3 antibodies (1:40)
and then permeabilized with 0.1% NP-40 for 15 minutes or
isotype control (Abcam Inc., Cambridge, MA) for one hour on ice,
and analyzed by flow cytometry (FACScan flow cytometer, BD
Biosciences, San Diego, CA).
Immunohistochemistry
With Mayo Clinic Institutional Review Board approval (IRB
1039-03), liver samples were obtained through the National
Disease Research Interchange (NDRI, Philadelphia, PA) from 10
HIV infected, 10 HCV infected, 10 HIV/HCV infected and 10
uninfected individuals. All patients were HBV negative and died of
unrelated traumatic causes. Anti-TRAIL and anti-TRAIL-R2
staining was performed in 10 mM citrate at pH 6.0 and 99 C for
20 min. To block non-specific antibody binding, sections were
incubated with blocking solution 1 [PBS, BSA 20 mg/ml (Serva,
Germany, Cat. No. 11924), human IgG 1 mg/ml Gamma-Venin,
(Aventis Behring)] for 20 min. Sections were then incubated
overnight at 4 C in blocking solution in the presence of the first
antibody or isotype-matched antibodies IgG1 and IgG2b at the
same concentration, both obtained from DakoCytomation
GmbH. Sections were washed twice in PBS and incubated with
blocking solution 2 [20% normal goat serum from Dianova
GmbH (Jackson ImmunoResearch Laboratories, Inc.)] for 20 min.
After blocking, sections were incubated with secondary biotiny-
lated antibody for 30 min at room temperature, rinsed twice for
5 min in PBS and incubated for 30 min with streptavidin-alkaline
phosphatase [Super-Sensitive Detection Kit, BioGenex San
HCV Hepatocytes Kill HIV Hepatocytes through TRAIL
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Ramon, CA (DCS Innovative Diagnostik-Systeme GmbH,
Hamburg, Germany)]. Thereafter, sections were rinsed twice in
PBS, incubated with fast red substrate (Fast Red Substrate System,
DakoCytomation GmbH) and counterstained with haematoxylin
(DakoCytomation GmbH).
Statistical Analysis
All results were expressed as the mean standard deviation (SD)
and repeated at least three times as indicated in the figures.
Statistical comparisons were made by student’s t test employed to
calculate the significance between the paired observations. A P
value of 0.05 was used as the level of significance.
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